Flexion Therapeutics Inc (NASDAQ:FLXN) insider Neil Bodick sold 5,000 shares of the firm’s stock in a transaction dated Friday, March 17th. The shares were sold at an average price of $20.41, for a total value of $102,050.00. Following the transaction, the insider now directly owns 50,937 shares in the company, valued at $1,039,624.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Neil Bodick also recently made the following trade(s):

  • On Friday, February 24th, Neil Bodick sold 5,000 shares of Flexion Therapeutics stock. The shares were sold at an average price of $19.15, for a total value of $95,750.00.
  • On Friday, January 20th, Neil Bodick sold 5,000 shares of Flexion Therapeutics stock. The shares were sold at an average price of $18.35, for a total value of $91,750.00.
  • On Wednesday, December 21st, Neil Bodick sold 10,000 shares of Flexion Therapeutics stock. The shares were sold at an average price of $18.46, for a total value of $184,600.00.

Flexion Therapeutics Inc (NASDAQ:FLXN) traded up 2.67% during mid-day trading on Monday, hitting $20.80. 147,961 shares of the stock were exchanged. The firm’s market capitalization is $660.00 million. The company’s 50-day moving average price is $19.73 and its 200 day moving average price is $18.95. Flexion Therapeutics Inc has a 52 week low of $7.68 and a 52 week high of $23.57.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/insider-selling-flexion-therapeutics-inc-flxn-insider-sells-5000-shares-of-stock.html

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings results on Thursday, March 9th. The specialty pharmaceutical company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.08. Equities research analysts expect that Flexion Therapeutics Inc will post ($3.46) EPS for the current year.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Your IP Address:

A number of research firms have recently weighed in on FLXN. Cantor Fitzgerald set a $37.00 target price on shares of Flexion Therapeutics and gave the stock a “buy” rating in a report on Monday, December 12th. BMO Capital Markets reiterated an “outperform” rating and set a $33.00 target price on shares of Flexion Therapeutics in a report on Thursday, December 15th. Janney Montgomery Scott reiterated a “buy” rating and set a $30.00 target price on shares of Flexion Therapeutics in a report on Saturday, March 11th. Raymond James Financial, Inc. began coverage on shares of Flexion Therapeutics in a report on Thursday, December 22nd. They set a “strong-buy” rating and a $35.00 target price for the company. Finally, Zacks Investment Research lowered shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 13th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Flexion Therapeutics has a consensus rating of “Buy” and an average target price of $28.55.

A number of hedge funds have recently made changes to their positions in the company. Keybank National Association OH boosted its stake in shares of Flexion Therapeutics by 0.7% in the fourth quarter. Keybank National Association OH now owns 10,357 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 67 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Flexion Therapeutics by 0.9% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 52,850 shares of the specialty pharmaceutical company’s stock valued at $1,005,000 after buying an additional 450 shares during the last quarter. Alps Advisors Inc. boosted its stake in shares of Flexion Therapeutics by 15.8% in the third quarter. Alps Advisors Inc. now owns 35,084 shares of the specialty pharmaceutical company’s stock valued at $686,000 after buying an additional 4,783 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Flexion Therapeutics by 6.3% in the third quarter. JPMorgan Chase & Co. now owns 119,050 shares of the specialty pharmaceutical company’s stock valued at $2,326,000 after buying an additional 7,075 shares during the last quarter. Finally, SECOR Capital Advisors LP bought a new stake in shares of Flexion Therapeutics during the third quarter valued at approximately $214,000. Institutional investors and hedge funds own 62.25% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

5 Day Chart for NASDAQ:FLXN

Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.